Kneat: Streamlining Compliance in Life Sciences
Kneat is redefining how life sciences companies handle regulatory compliance, one digital document at a time.
Digital validation software gains traction across major pharmaceutical giants
In an industry where every step must be documented and regulatory compliance is non-negotiable, Kneat is helping life sciences companies reduce costs and improve accuracy. Their digital validation platform has become the go-to choice for eight of the ten largest pharmaceutical companies worldwide. With customers like Merck rolling out Kneat across 27 global sites and over 12,000 users, the company is scaling rapidly. Offering a significant reduction in cycle time, documentation labor, and compliance errors, Kneat has seen its revenue climb 32% year-over-year in 2025. And with market penetration still low, the $2B total addressable market for digital validation remains largely untapped.
To learn more about Kneat.com, Inc. (TSX: KSI, OTC: KSIOF), watch their video HERE
Published by BTV - The Agency
Discover Investment Opportunities with BTV. Delivering engaging content to Investors for 25+ years.
.jpg)
You might also like
Critical Elements Lithium Poised to Support Growing Demand Beyond EVs
Critical Elements Lithium is ready to fuel tomorrow’s energy by advancing its Rose Lithium-Tantalum Project in Quebec. The company’s focus is on producing high-purity spodumene concentrate to supply the flourishing electric vehicle and energy storage systems industries.
Critical Elements Lithium: Is Quebec ready to deliver new North American supply?
Global lithium demand is expected to rise from roughly 1.2 million tonnes in 2025 to about 3 million tonnes by 2030, driven largely by electric vehicles and energy storage for ravenous data centres and artificial intelligence. Management believes supply will struggle to keep pace, creating room for new producers with near-term projects.
Harvest HPYB ETF Income From Canadian Banks
Harvest Premium Yield Canadian Bank ETF (HPYB) is built to generate higher income from Canadian bank stocks by combining bank exposure with an active options strategy that sells calls and puts, producing more tax-efficient cash flow than dividends alone.